LANTERNA Announces the Appointment of Horace Hale B.A. Sc., to the Post of President

LANTERNA News >>

SAINT GALLEN – Lanterna Medical Technologies (Feb.01, 2013)

Lanterna Medical Technologies, a medical device company focused on developing innovative and intuitive and cost effective solutions for spine disease, announced today, the appointment of Mr. Horace W. Hale to the post of president.

Mrs. K.L. Hale B.A., M.B.A. (Lond.), managing director of Lanterna said, “We are extremely fortunate and excited to have such an experienced and well versed professional as a member of our team.

Mr. Hale brings a proven track record of building value and creating innovative new ideas for treatment modalities as well as marketing methods.

His extensive knowledge of the worldwide orthopedic implant market and his creative innovations will be welcomed additions that will further bolster the depth and experience of our company.


As we begin to execute on our market share taking strategy, we look forward with great anticipation, to Mr. Hale’s contributions.

Prior to joining Lanterna, Mr. Hale held several senior sales and management positions with Kyphon, Smith and Nephew and Johnson and Johnson both in North America and the E.M.E.A. region.

Mr. Hale has been singularly responsible for the introduction of many new and innovative spinal treatment modalities to the art and science of the surgical treatment of spine disease.

Mr. Hale is the proud holder of 4 issued patents both in the USA and internationally (Including Japan) in the area of ¨FACET  RESURFACING TECHNOLOGY¨.

LANTERNA cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause LANTERNA’S results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that LANTERNA’S revenue or earnings projections may turn out to be inaccurate because of the preliminary nature of the forecasts; the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability; and other risks and uncertainties more fully described in LANTERNA’S press releases.

LANTERNA assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Back